Antidrug antibody incidence during the study
| ABP 501 (n=67) | Adalimumab (USA) (n=69) | Adalimumab (EU) (n=67) | |
|---|---|---|---|
| Day 1 | |||
| Binding antibody assay positive, n (%) | 0 | 0 | 0 |
| Neutralising antibody assay positive, n (%) | 0 | 0 | 0 |
| Day 16 | |||
| Binding antibody assay positive, n (%) | 12 (17.9) | 12 (17.4) | 23 (34.8) |
| Neutralising antibody assay positive, n (%) | 0 | 0 | 0 |
| Day 29 | |||
| Binding antibody assay positive, n (%) | 21 (31.8) | 27 (41.5) | 27 (41.5) |
| Neutralising antibody assay positive, n (%) | 0 | 0 | 2 (3) |
| End of study (day 63) | |||
| Binding antibody assay positive, n (%) | 29 (43.3) | 34 (50.0) | 34 (50.7) |
| Neutralising antibody assay positive, n (%) | 12 (17.9) | 15 (21.7) | 13 (19.4) |
| Anytime | |||
| Binding antibody assay positive, n (%) | 36 (53.7) | 38 (55.1) | 45 (67.2) |
| Neutralising antibody assay positive, n (%) | 12 (17.9) | 15 (21.7) | 14 (20.9) |